Jarrod D. Longcor - 07 May 2026 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Reporting relationship: Chief Operating Officer
Issuer ticker: CLRB
Reported as of: 07 May 2026
Net transaction value: +$24,998
SEC form: 4
Accepted by SEC: 11 May 2026, 20:07:18 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Christina Blakley, attorney-in-fact for Jarrod D. Longcor

Key filing fact

Jarrod D. Longcor filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 11 May 2026.

Key facts

This page summarizes Jarrod D. Longcor's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 May 2026, 20:07.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: +$24,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001545565 Primary reporting owner

Longcor Jarrod

Relationship: Chief Operating Officer
Address: C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK
Signature: /s/ Christina Blakley, attorney-in-fact for Jarrod D. Longcor
Signature date: 11 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLRB transaction

Common Stock

Purchase

Transaction value: $24,998
Shares: +8,680
Change %: +74%
Price: $2.88
Shares after: 20,451
Date: 07 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLRB transaction Derivative

Warrants

Purchase

Transaction value
Shares: +26,040
Change %: +258%
Price: $0.0100^*
Shares after: 36,149
Date: 07 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,040
Exercise price: $2.88
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Expiration dates are as follows: Tranche A shall have a one-year term from the date of stockholder approval; Tranche B shall have a two-year term from the date of stockholder approval; Tranche C shall have a five-year term from the date of stockholder approval.